SCIENCE @ ImmunoACT
Our technology
Unique platform to craft novel humanized CAR
Manufacturing patient-scale CAR-T cells in cGMP compliant settings: ensuring high quality CAR-T cells to all patients
Actual image of CAR (HCAR19)
Actual image of CAR (HCAR19)
Problem
-
Cancer treatment remains a challenge through conventional therapies leading to high mortality.
-
CAR-T cells, a type of cell and gene therapy with "intent to cure" platform are not available at any price in India and other countries with low-resources.
-
Cost of available CAR-T cell therapy overseas is prohibitive (~400,000-500,000 USD per patient).
-
Additional costs of ancillary services (intensive-care unit etc.) makes CAR-T cell therapy extremely expensive (~1million USD per patient).
-
Majority of the commercially available CAR-T cell therapies are also associated with severe toxicity profile.
Our Solution
-
CAR-T cell therapy is highly efficacious in curing certain cancers especially Leukemia and Lymphoma, and is a globally proven technology.
-
From ideation to clinic-ready products: core of our innovation.
-
ImmunoACT's patented CAR-T cell platform provides a unique design algorithm to develop novel CAR-T cells.
-
ImmunoACT's first product, HCAR19, showed favourable balance of efficacy and toxicity.
-
Our unique GMP-compliant manufacturing process allows us to produce high-quality affordable CAR-T cells.
